摘要
背景:在发达国家,治疗和护理痴呆患者的经济负担问题至关重要。欧盟和其他发达国家正在努力改善人口老龄化的进程,从而导致成本上升。它们的统一登记也是发达国家防治痴呆症战略计划的目标之一。到目前为止,这些计划的个别步骤主要是针对疾病的早期诊断,相关数据的记录到目前为止都处于背景中。目的:本文件的目的是规定一套应在国家一级不断监测的老年痴呆症费用。方法:以阿尔茨海默病为研究对象,对阿尔茨海默病进行文献综述。搜索的关键词是“阿尔茨海默病”和“2010年以后发生的费用”。这些研究将具体说明所监测的费用并确定其最低普及率,从而构成在国家一级为被监测的费用组提出建议的基础。结果:分析结果显示,监测的主要费用类别如下:医疗直接费用(住院治疗、门诊治疗、药物治疗)、非医疗直接费用(日托中心、社区卫生服务、临时护理、病人住宿费用)和间接费用(护理人员专用于病人的时间)。不同名称和费用组的问题要求在这一领域制定共同战略,并确定应监测的最低项目。
关键词: 成本分类,痴呆症,老年痴呆症,直接成本,间接成本,衰老。
Current Alzheimer Research
Title:Missing Uniform Costs Classification for Alzheimer’s Disease Treatment and Care
Volume: 15 Issue: 14
关键词: 成本分类,痴呆症,老年痴呆症,直接成本,间接成本,衰老。
摘要: Background: The importance of the issue of the economic burden of treatment and care for people with dementia is crucial in the developed countries. The European Union and other developed countries are trying to improve the course of aging population which leads to rising costs. Their uniform registration is also one of the objectives of the developed countries’ strategic plans to fight dementia. The individual steps of the plans in practical terms so far are mainly directed to the early diagnosis of diseases, records of the associated data are so far in the background.
Aim: The aim of this paper is to specify a set of costs that should be constantly monitored at the national level within dementia.
Methods: The main method is a literature review focused on Alzheimer's disease. The searched keywords were "Alzheimer's disease" and "costs" incurred after 2010. The studies will specify the monitored costs and determine their minimal penetration, which will then form the basis for recommendations for the monitored group of costs on a national level.
Results: Results of the analysis indicate that the following main cost groups are monitored: medical direct costs (inpatient care, outpatient treatment, medication), non-medical direct costs (day care centres, community health services, respite care, accommodation costs for patients) and indirect costs (time that the carers dedicate to the patient). The issue of different naming and groups of costs calls for a common strategy in this area and defining the minimum items that should be monitored.
Export Options
About this article
Cite this article as:
Missing Uniform Costs Classification for Alzheimer’s Disease Treatment and Care, Current Alzheimer Research 2018; 15 (14) . https://dx.doi.org/10.2174/1567205015666180831103018
DOI https://dx.doi.org/10.2174/1567205015666180831103018 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimers Disease and Retinal Neurodegeneration
Current Alzheimer Research Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Role of Cdk5 in Amyloid-beta Pathology of Alzheimer’s Disease
Current Alzheimer Research Cerebral Microinfarcts and Dementia: A Systematic Review and Metaanalysis
Current Alzheimer Research Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Melatonin and Regulation of Immune Function: Impact on Numerous Diseases
Current Aging Science The Effect of <i>Stachy sieboldii</i> MIQ. Supplementation on Modulating Gut Microflora and Cytokine Expression in Mice
Combinatorial Chemistry & High Throughput Screening Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Transgenic Overproduction of Omega-3 Polyunsaturated Fatty Acids Provides Neuroprotection and Enhances Endogenous Neurogenesis After Stroke
Current Molecular Medicine The Neuroinflammatory Response in Plaques and Amyloid Angiopathy in Alzheimers Disease: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders Neuroprotection Abilities of Cytosolic Phospholipase A2 Inhibitors in Kainic acid-induced Neurodegeneration
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of Pericytes in Neurovascular Unit: Emphasis on Stroke
Current Drug Targets Prevalence of Neuropsychiatric Symptoms in Alzheimers Disease and Vascular Dementia
Current Alzheimer Research Protein Aggregation: Elucidation of the Mechanism and Determination of Associated Thermodynamic and Kinetic Parameters
Current Physical Chemistry Extraction, Structure and Bioactivities of the Polysaccharides from Fructus corni
Recent Patents on Food, Nutrition & Agriculture Retinoic Acid and the Gut Microbiota in Alzheimer’s Disease: Fighting Back-to-Back?
Current Alzheimer Research Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer’s Disease Therapy: Advances in Chemical and Biological Research
Current Medicinal Chemistry Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke
Cardiovascular & Hematological Disorders-Drug Targets Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued)